Skip to content

Regeneron Pharmaceuticals

US · REGN #285 by market cap Listed 1970
920.69 -1.71 -0.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 77 in the most recent period (2026/Q3).
  • Total institutional ownership fell 0.6 percentage points.

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
93.13% -0.60pp
Institutions
1,751 +77
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund77.94%
Hedge Fund4.59%
Public Company3.94%
Individual/Insider3.80%
Government Pension Fund2.54%
Private Company1.84%
Sovereign Wealth Fund1.26%
Insurance Company0.42%
Family Office/Trust0.18%
Other3.48%

Top holders as of 2026-06-30

BlackRock 9.08% · 9.11M sh
Vanguard Capital Management, LLC 7.17% · 7.19M sh
Dodge & Cox 4.85% · 4.87M sh
State Street Global Advisors 4.82% · 4.83M sh
Invesco Capital Management LLC 3.23% · 3.24M sh
Other 70.71%
Vanguard Portfolio Management, LLC 3.16% · 3.18M sh
J.P. Morgan Asset Management, Inc. 3.15% · 3.16M sh
Geode Capital Management, LLC 2.62% · 2.63M sh
Leonard Schleifer 2.41% · 2.41M sh
Putnam LLC 2.30% · 2.31M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 18 buys · 32 sells

NameRoleStake
Leonard Schleifer Co-Founder, President, CEO & Co-Chairman 2.41%
George Yancopoulos Co-Founder, President, Chief Scientific Officer & Co-Chairman 1.16%
Andrew Murphy Executive VP of Research & Co-Chief Scientific Officer 0.05%
Joseph LaRosa General Counsel 0.04%
Daniel Van Plew Executive VP and GM of Industrial Operations & Product Supply 0.04%
George Sing Independent Director 0.03%
Christopher Fenimore Chief Financial Officer 0.03%
Michael Brown Independent Director 0.01%
Marion McCourt Executive Vice President of Commercial 0.01%
Robert Landry Former Chief Financial Officer 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-03 Jason Pitofsky Senior Vice President Open Market Disposition -179 $950.76
2026-11-03 Jason Pitofsky Senior Vice President Derivative Exercise and Sale -3,883 $492.00–945.61
2026-11-02 Andrew Murphy Executive VP of Research & Co-Chief Scientific Officer Other Disposition -1,054 --
2026-11-02 Huda Zoghbi Independent Director Derivative Exercise and Sale -7,439 $380.95–971.06
2026-11-01 Christopher Fenimore Chief Financial Officer Derivative Exercise and Sale -4,258 $381.92–950.50
2026-11-01 Christopher Fenimore Chief Financial Officer Derivative Exercise and Retained +1,742 $381.92
2026-11-01 Christine Poon Lead Independent Director Derivative Exercise and Sale -7,830 $376.69–971.31
2026-11-01 George Sing Independent Director Open Market Disposition -5,860 $965.38–970.18
2026-11-01 George Sing Independent Director Derivative Exercise and Sale -15,269 $376.69–965.38
2026-11-01 Joseph LaRosa General Counsel Open Market Disposition -869 $965.41–966.11
2026-11-01 Joseph LaRosa General Counsel Derivative Exercise and Sale -12,283 $381.92–965.41
2026-10-29 Michael Brown Independent Director Derivative Exercise and Sale -1,929 $725.89–875.00
2026-10-29 Marion McCourt Executive Vice President of Commercial Automatic Disposition -1,132 $869.43
2026-10-29 Kathryn Guarini Independent Director Derivative Exercise and Sale -400 $719.37–900.00
2026-10-13 Andrew Murphy Executive VP of Research & Co-Chief Scientific Officer Derivative Exercise and Sale -17,000 $381.92–781.47
2026-10-13 Andrew Murphy Executive VP of Research & Co-Chief Scientific Officer Intent to Sell (Form 144) -4,147 $772.70
2026-09-02 Marion McCourt Executive Vice President of Commercial Automatic Disposition -2,346 $850.00–857.39
2026-09-02 Marion McCourt Executive Vice President of Commercial Intent to Sell (Form 144) -1,131 $857.00
2026-09-01 Marion McCourt Executive Vice President of Commercial Intent to Sell (Form 144) -1,215 $850.00
2026-09-01 Kathryn Guarini Independent Director Derivative Exercise and Sale -400 $719.37–850.00

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.

Regeneron Pharmaceuticals discussion 0 comments

Add a comment